INTRODUCTION
The recommended goal of nutrition support for very-low-birthweight (VLBW) infants from birth to term age is to match the in utero growth rates of the normally growing fetus. 1 This goal is rarely achieved in the VLBW infant. 2 -5 Recent studies indicate that, in fact, almost all VLBW infants experience postnatal growth failure. 6 -8 In one study of extremely low-birth-weight infants <1000 g, 99% were classified as growth-restricted ( <10%) at 36 weeks postnatal age. 7 In addition, VLBW infants exhibit suboptimal growth after discharge. 3,7 -10 In the past, full-term infant formulas were used after discharge for most premature infants. However, infants are now discharged at lower body weights than in the past. There is evidence that full-term formulas do not adequately meet the nutritional needs of these infants after discharge. Although transitional formulas (TFs) are now available for premature infants after discharge, the AAP has not yet made recommendations regarding their use. The AAP has, however, acknowledged that the discharge formula prescription for premature infants needs to be reevaluated. 1 Lucas et al. 10 conducted a randomized, double-blind trial in a cohort of preterm infants less than 1850 g at birth to a postnatal age of 9 months. He demonstrated weight and linear growth advantages for infants receiving enriched ''postdischarge'' formula compared to standard formula (SF) for full-term infants. There are, however, limited data on the effects of the introduction of a high-nutrient TF for VLBW infants at the time of discharge on subsequent growth.
Upon admission to the Women and Infants Hospital Neonatal Intensive Care Unit (NICU), mothers of VLBW infants are informed of the benefits of human milk and encouraged to have human milk available for their babies' feedings. Depending on the success and wishes of the mother, infants subsequently receive either human milk±fortifiers, preterm formulas, or a combination of human milk+preterm formula. It is not until the time of discharge that TF is introduced.
A high-nutrient TF for VLBW infants was first introduced into the Women and Infants Hospital NICU in 1995. The TF was started within the week before discharge or when the baby weighed at least 1850 g. The objective of this study was to assess the impact of TF started at discharge on growth in the first 18 months of life. It was hypothesized that VLBW infants receiving the TF would have more optimal growth than VLBW infants receiving standard term formula
after discharge. Second, it was hypothesized that VLBW infants fed TF would have higher Bayley 11 scores at 7 and 18 months corrected age (CA) compared to VLBW infants receiving SF.
METHODS
The study was a retrospective chart review of medical records to identify and compare two groups of infants based on formula prescribed at discharge. Infants were evaluated in the Neonatal Follow-Up Clinic at 3, 7, and 18 months CA. The sample included all 180 VLBW infant survivors born between January 1, 1995 and December 31, 1996. Sixty-six infants (37%) were discharged on TF±human milk, and 114 infants (63%) were discharged on standard term formula±human milk, or, in rare exceptions, premature formulas or other specialty formula±hu-man milk. At the time of the study, Similac NeoSure was the only TF available. The nutrient composition of the four formulas most frequently prescribed at discharge is shown in Table 1 . Approximately 85% of infants received these formulas at discharge. The remainder were on other standard concentration formula. The TF contains higher amounts of protein, Ca, P, and several trace minerals and vitamins than the others. The recommendation to use TF for premature infants was introduced to the attendings, fellows, and nurse practitioners in the spring of 1995. After discharge, the Women and Infants Hospital Follow-Up Clinic recommendations were to remain on TF until the infant's linear grown was between the 25th and 50th percentile for CA and the infant was able to consume at least 26 oz of formula per day. Enteral nutritional intake for the study sample was coded to distinguish between infants on TF±human milk or any combination of SF±human milk. Daily weights for a 3-day period were collected from the medical records at the time of first enteral feed and at 32, 34, and 36 weeks CA. Mean 3-day weight was calculated. Protein and caloric intakes were collected from the hospital records for the same 3-day periods and mean 3-day intakes were calculated. These data were collected as baseline to ensure comparability of the study groups at discharge. Additional data points included weight, length, and head circumference at birth, discharge, and at 3, 7, and 18 months CA. Maternal and neonatal characteristics, and type of formula provided at 3, 7, and 18 months were recorded. Data on the intake of solids and the quantity of formula ingested postdischarge were not collected.
Anthropometrics
Weight was measured on a standard infant scale with the infant naked. Head circumference (the largest occipito-frontal diameter) was measured with a flexible tape. Length was measured using an infantometer. Length was measured to the 10th of a centimeter. The z-scores for weight and length for both study groups were calculated using National Center for Health Statistics age-and gender-specific growth data as the reference. Anthropometric examiners were not aware of the study design.
The Bayley Scales of Infant Development (BSID II), 11 including the mental and motor scales, were administered. The Bayley scores of 100±15 represent the mean±1 SD for a mental developmental index (MDI) and a psychomotor developmental index (PDI). A Hollingshead SES score 12 derived from maternal and paternal education, and maternal and paternal occupation, was calculated for each family. Bayley examiners were not aware of the infants' dietary intake.
Data analysis consisted of t-tests, ANOVAs, ANCOVAs, and repeated measures analyses for continuous variables and chi-square analysis for categorical variables. Total group analyses, analyses for small for gestational age (SGA) and appropriate for gestational age (AGA) subgroups, and analyses for subgroups based on duration of TF intake were completed. Backward elimination linear regression analysis was used to predict weight, length, and head circumference at 3, 7, and 18 months CA.
The study was approved by the Women and Infants Hospital Institutional Review Board.
RESULTS
There were no differences between the two study groups for SES, maternal age, race, marital status, maternal education, and prenatal care (not shown) Seventy-one percent of the TF mothers and 83% of the SF mothers were high school graduates. Worrell et al.
High-Nutrient Transition Formula in VLBW Infants
Neonatal characteristics are shown in Table 2 . Infants in the two groups were similar in terms of neonatal characteristics. Morbidities were also similar except that infants in the TF group had a higher incidence of chronic lung disease than the SF group (27% vs 15%, p<0.04) respectively. Thirty-six percent of the TF group was SGA ( <10th percentile for weight) at birth compared to 25% of the SF group. Mean weights were similar at discharge. At discharge, 9% of the TF group and 11% of the SF group were receiving some human milk. Infants in the two study groups had essentially equivalent nutritional intakes of protein and calories during the hospitalization. Use of TF increased from 10% in 1995 to 66% in 1996, p<0.001.
Use of human milk decreased significantly after discharge. The percentages of mothers providing any human milk at discharge, 3, 7, and 18 months were 9.1%, 9.1%, 3.7%, and 0% for the TF group and 10.5%, 10.9%, 1.2%, and 0% for the SF group.
Mean head circumference, weight, and length at 3, 7, and 18 months CA are shown in Table 3 . Repeated measures analyses were completed. Overall group effects were identified for length, and length was significantly greater for infants in the TF group than the SF group at 18 months CA (81.7±3.6 vs 80.1±4.4 cm, p<0.02). There were no significant group effects in weight or head circumference at any age. When separate ANOVAs were completed for growth parameters dividing both groups into SGA and AGA subgroups, the differences for length remained significant for both the AGA and SGA subgroups (82.5±3 vs 80.9±4 cm, p<0.04 and 80.2±3 vs 77.8±4 cm, p<0.058), respectively. Differences in mean length were 1.6 cm for AGA TF and SF groups and 2.4 cm for SGA TF and SF groups (Figure 1 ). The z-scores for weight and length at 3, 7, and 18 months CA are shown in Figure 2 , confirming the greater length adjusted for gender and age of infants in the TF group. For all study groups, growth parameters were significantly below the mean that would be expected based upon data from the National Center for Health Statistics.
Subgroup analyses of growth parameters were done by ANOVA at 18 months with groups formed by how long postdischarge they were on TF: no TF, TF at discharge, TF to 3 months, or TF to 7 months. Differences among the four subgroups were not significant for weight and borderline for length, p=0.08. Lengths at 18 months for infants with no TF, TF at discharge, TF to 3 months, and TF to 7 months old were 80.1, 81.3, 82.3, and 82.1 cm.
Backward elimination linear regression models were developed to identify predictors of growth at 3, 7, and 18 months of age. Independent variables entered into the models included anthropometrics at birth (weight, length, and head circumference), SGA versus AGA status, proven sepsis, necrotozing enterocolitis, need for O 2 at 36 weeks, postnatal steroids, postdischarge human milk use, and type of formula (TF versus SF) at discharge. Two additional variables, which may impact on growth (parental stature and intake of solids), were not available. Table 4 shows the results of the backward elimination models for weight, length, and head circumference. Birth weight, SGA status, and TF at discharge remained in the model for weight at 3 months. Use of TF was associated with 0.34 kg greater weight at 3 months ( p=0.029). Birth weight and SGA status were the only significant predictors of weight at 7 and 18 months. Birth length and SGA status were significant predictors of length at 3, 7, and 18 months. At 3 months postdischarge, human milk had a negative impact on length (b= À0.25, p=0.001). At 18 months, TF was a significant predictor of length. In fact, the use of TF was associated with a mean benefit of 1.90 cm greater length at 18 months ( p=0.0056). Head circumference at birth, SGA status, and postdischarge human milk were predictors of head circumference at 3 months. Both SGA status and human milk were negatively associated with head circumference. Birth head circumference and SGA status remained in the model at 7 and 18 months.
The impact of continued use of TF at 3 and at 7 months on growth parameters at 18 months was also analyzed by backward elimination regression, although most infants in this sample received the TF for a relatively short time after discharge. Of the 66 infants started on TF at discharge, 58% remained on TF at 3 months, 37% at 7 months, and none at 18 months. Use from discharge to 3 months had an effect on length at 18 months (b=2.1 p=0.01), as did continued use from discharge to 7 months (b=2.6 p=0.004). Continued use analysis demonstrated no effects for weight and head circumference.
There were no differences in Bayley MDI or PDI scores between the TF and SF groups at 7 or 18 months CA based on t-tests or continued use analyses. Scores at 18 months were 81±16 vs 85±17 for MDI and 81±13 vs 83±15 for PDI for the TF and SF groups, respectively. ANCOVA of 18-month Bayley scores with TF and SF as primary groups and with postdischarge human milk as covariant was 
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DISCUSSION
Because of the known growth delays of premature infants, 2 -10 there have been continued efforts to develop better nutritional support both in the NICU and after discharge. 2 -5,8 -10,13 -17 This study documented a rapid acceptance between 1995 and 1996 by the neonatologists from a single tertiary care center to use a newly introduced TF at discharge. However, unfortunately, its continued use was limited to 58% of infants at 3 months and 37% at 7 months. This reflects the fact that continued use of TF after discharge was primarily at the discretion of the primary care providers. Although dietary intake and growth were reviewed both by the nutritionist and physician with the parents during the Follow-Up Clinic visits, there was some resistance to the ''new formula'' and recommendations provided by clinic staff were not always followed by the primary care provider. Despite the limited use of the TF, z-score values for weight and length after discharge for infants who received TF were consistently closer to the median compared to the infants in the SF group.
Our data also show beneficial effects of TF on linear growth for both AGA and SGA infants. At 18 months, SGA infants in the TF group were 2.4 cm longer compared to SGA infants who received SF. AGA infants in the TF group were 1.6 cm longer than AGA infants who received SF. The benefit in length between formula groups was 0.8 cm greater for SGA infants than for AGA infants. This may indicate that among VLBW infants, SGA infants would benefit even more than AGA infants from the use of TF or other nutrient/calorieenhanced formula. There has been an often-held view that SGA infants are destined ''to follow their own growth curve.'' Two largescale studies support the view that SGA infants remain smaller through early childhood. 17, 18 However, TF was not available during either study. Our findings suggest that the growth of SGA infants provided high-nutrient formula may be potentiated. The most interesting findings of this study are reflected by the results of the backward elimination regression analyses. It was not surprising that the birth anthropometrics and SGA status at birth impacted on growth after discharge. However, we confirmed that after controlling for confounders, the use of TF had a significant positive effect on the infants' weight at 3 months (0.33 kg) and on length at 18 months (1.6 cm). Further, the longer the infants remained on TF, the greater the benefit to linear growth. On repeated measures analyses, we identified a linear difference of 1.6 cm at 18 months; this difference is clinically significant because it could make the difference between length at the 5th percentile versus length at the 10th percentile.
Limited data exist regarding growth and body composition of preterm infants after hospital discharge. Before TF became available, Georgieff et al. 19 reported that AGA VLBW infants fed standard infant formula after discharge remained smaller during the first year of life than LBW infants and infants who weighed >2500 g at birth. At 4 and 12 months, VLBW infants had significantly less body fat than normal birth weight infants. They did, however, grow proportionately during the first year. The authors concluded that growth of VLBW infants in the first year was related more to muscle accretion than to fat deposition.
A recent study followed 60 VLBW AGA infants with bronchopulmonary dysplasia (BPD) until 3 months CA in a randomized trial. 20 One group of infants received a nutrient-enriched formula, while the other received a SF. Nitrogen and mineral retention at 38 weeks' gestational age was significantly greater in infants who received the enriched formula. By 3 months CA, infants in the enriched formula group were significantly longer, had significantly greater radial bone mineral content, and had significantly greater lean body mass. Infants with BPD who were fed an enriched nutrient formula experienced faster catch-up growth than if they had been fed SF. The authors concluded that the growth failure common in infants recuperating from BPD is related to inadequate nutrient intake rather than either malabsorption of nutrients or inadequate calories. In our study, there were significantly more infants with BPD (O 2 at 36 weeks) in the study TF group. This fact suggests that our observed growth differences may have been even greater had our study groups been evenly matched for perinatal risk. It also indicates that there may have been an inadvertent selection bias for TF in our retrospective cohort because house staff were more likely to start infants with BPD or infants who were SGA on TF than SF. In addition, a higher proportion of the TF group than the SF group that returned at 18 months had a history of O 2 requirement at 36 weeks (33% vs 18%, p<0.04), respectively.
In our study, body weight trended higher for the TF group at 3 months CA. The lack of significant differences may be because sample size was small (limited power) to detect true differences in weight between the groups and because the use of TF was discontinued too early. Only 58% of infants discharged with TF still received it at 3 months. Despite the fact that the power for explaining the amount of variance in the regression (R 2 =0.22) was better than 90%, and the power for detecting TF effects (the power of the TF coefficient) was 69%, our backward elimination linear regression model revealed a significant effect of TF formula on weight at 3 months.
Although infants in the TF group were longer than those in the SF group at 3, 7, and 18 months, the difference was significant only at 18 months. We propose that because of a relative state of deficient bone mineralization in VLBW infants at the time of discharge from the NICU, the process of effective ''catch up'' of length may be prolonged and therefore significant effects of TF on linear growth were first demonstrated at 18 months. Although we did not measure bone density or body composition, the infants who received TF in our study received significantly greater intakes of both calcium and phosphorus, which have been shown to result in greater radial bone mineral content. 10, 21 A limitation of our study is the lack of information about nonformula foods the infants received after discharge. Solid foods typically given to infants first, such as cereal, fruits, and vegetables, are relatively low in protein, calcium, and phosphorus. SFs and human milk have a lower nutrient density than TF. As others have shown, 21, 22 consumption of solid foods or a change to a diet of SF or human milk with or without supplemental TF would have lowered the mean nutrient intake for infants in the TF group.
In addition, we believe that feeding issues for former VLBW infants may be even more challenging than those for children whose birth weights were normal, and we propose a second explanation for the lack of early findings for length. We speculate that children from the TF group may have entered the developmental phase (12-18 months) in better nutritional status than children in the SF group and may have been able to withstand nutrient shortfalls that accompany learning to self-feed. This may have enabled children from the TF group to better maintain linear growth from 12 to 18 months.
Several authors 15, 16 have reported short-term beneficial effects of using premature infant formula after discharge. Wheeler and Hall 15 conducted a randomized, double-blind study comparing standard 20 kcal/oz infant formula to 20 kcal/oz premature infant formula for 8 to 12 weeks postdischarge in a sample of 42 infants <1800 g birth weight. They found that the infants fed premature formula had greater length and head circumference than the infants fed SF. Cooper et al. 16 reported greater weight, length, and head circumference measurements at 5 weeks in infants <1000 g birth weight fed premature formula.
Our results are similar to other studies 8, 13, 14 that evaluated the effects of a high-nutrient formula after discharge. Friel et al. 13 reported on 52 infants <1500 g birth weight who were randomly assigned to either a nutrient-enriched formula or a standard term formula when the infants achieved a weight of 1850 g. Infants were then maintained on the assigned formula for 6 months and followed for 12 months. They reported better weight gain velocity during the first 8 days in the study for infants on high-nutrient formula with a trend for better length velocity z-scores after discharge.
Lucas et al. 14, 27 conducted a randomized, double-blind trial on preterm infants <1850 g at birth. Infants were randomized to receive either SF or a special ''follow-on preterm formula'' for 9 months. Infants on the enriched formula were more likely to have achieved better linear growth compared to the SF infants (1.1 cm difference) and higher weight (370 g difference) at 9 months of age.
In a randomized trial, Carver et al. 8 compared a nutrientenriched formula to standard term formula provided to 12 months CA in a sample of 125 infants <1800 g. They found greater benefits to growth from the nutrient-enriched formula in infants with birth weight <1250 g and in male infants.
The VLBW infants in our study who were in the TF group had Bayley scores similar to the infants in the SF group. In the trial of Lucas et al., 27 they found no significant differences in Bayley scores at 9 and 18 months between infants receiving an enriched postdischarge formula compared to SFs. We did, however, identify a positive effect of human milk postdischarge on the Bayley MDI at 18 months. This positive influence of human milk on early development is consistent with the findings reported by others. 23, 24 The results of our backward elimination linear regression revealed that human milk was a confounder for both 3-month length and head circumference despite the fact that infants in our NICU who receive human milk receive human milk fortifier or supplemental preterm formula. Studies comparing unfortified and fortified human milk with fortified formulas have shown decreased bone mineralization and linear growth among infants receiving human milk. 10, 21, 25, 26 In summary, our findings support prior reports 8, 13, 14 of improved growth for VLBW infants receiving TF. One difference between our observational study and the three trials was duration of TF. In the Friel et al. 13 trial, infants received TF for 6 months, in the Lucas et al.
14 trial for 9 months, and in the Carver et al. 8 trial for 12 months. In our study, only 37% of infants remained on TF at 7 months of age. Our analyses of effects of duration of TF administration indicate that duration of intake is an important modifier and that continuation of enhanced nutrient intake for the first 7 months is beneficial for VLBW infant growth.
Given that this was an observational study design and that quantitative measurements of nutritional intake postdischarge were not available, a definitive conclusion cannot be drawn. However, perhaps it should be noted that the TF group had better anthropometric measurements at each follow-up point, their z-scores were closer to the NCHS medians for length and weight at each time point, and a significant advantage was found for length at 18 months despite the fact that there was more chronic lung disease in the TF group. Although our findings are limited by study design, they are highly suggestive and indicate the need for further randomized, controlled prospective studies to define the guidelines for what types of diet are needed and how long they should be used after discharge to optimize the nutritional status of VLBW infants.
